Sanofi provides update on venglustat clinical program
Sanofi provides update on venglustat clinical program PARIS – JUNE 1, 2021 – A pivotal Phase 2/3 study of venglustat in autosomal dominant...
Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sanofi provides update on venglustat clinical program PARIS – JUNE 1, 2021 – A pivotal Phase 2/3 study of venglustat in autosomal dominant...
Share this article Share this article BRIDGEWATER, N.J. and KENILWORTH, N.J., June 1, 2021 /PRNewswire/ -- Vaxelis™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine), developed as part of a partnership between Sanofi Pasteur, the global vaccines business unit of Sanofi, and Merck (NYSE: MRK), * known as MSD outside the United States and Canada, is now available in the U.S. Vaxelis is the first and only hexavalent (six-in-one) combination vaccine available in the U.S. Vaxelis is a vaccine given to protect your c...
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well
Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identif...
no ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s notable to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.” In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER...